Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion


As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray…

Share post:



More like this

NJ Transit, Amtrak service suspended through New York due to power issues

PATH is also reporting "network connection" issues on the...

Trump Media plummets 15% as DJT stock sell-off deepens

Trump Media has been in a slump since a...